Covered recipient · General Payments record
CALEB JEON
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2020–2024
$2,127.17
- Reported across 75 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $577.75 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $181.88 | 9 |
| E.R. Squibb & Sons, L.L.C. | $111.08 | 1 |
| GENZYME CORPORATION | $103.19 | 1 |
| Lilly USA, LLC | $81.07 | 3 |
| Incyte Corporation | $26.80 | 1 |
| PFIZER INC. | $26.00 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $25.18 | 1 |
| Dermavant Sciences, Inc. | $22.55 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $11.40 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994449 | CMS |
| ABBVIE INC. | $10.49 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994451 | CMS |
| ABBVIE INC. | $15.47 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994453 | CMS |
| ABBVIE INC. | $26.10 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994455 | CMS |
| ABBVIE INC. | $31.48 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994457 | CMS |
| ABBVIE INC. | $8.31 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994459 | CMS |
| ABBVIE INC. | $20.66 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994461 | CMS |
| ABBVIE INC. | $32.36 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994463 | CMS |
| ABBVIE INC. | $25.61 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103994465 | CMS |
| Dermavant Sciences, Inc. | $22.55 | 03/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127884351 | CMS |
| E.R. Squibb & Sons, L.L.C. | $111.08 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101208650 | CMS |
| GENZYME CORPORATION | $103.19 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139913761 | CMS |
| Incyte Corporation | $26.80 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141295594 | CMS |
| Lilly USA, LLC | $23.72 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136082920 | CMS |
| Lilly USA, LLC | $26.20 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136082922 | CMS |
| Lilly USA, LLC | $31.15 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136083200 | CMS |
| PFIZER INC. | $26.00 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131390540 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $25.18 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152132544 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2020 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.